<DOC>
	<DOCNO>NCT00428077</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build effective immune response kill cancer cell . PURPOSE : This phase II trial study well vaccine therapy work treat patient chronic phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine antileukemic effect tumor-specific Breakpoint Cluster Region-Abelson Murine Leukemia ( BCR-ABL ) junction specific peptide vaccine , measure decrease circulate BCR-ABL transcript reverse-transcriptase polymerase chain reaction ( RT-PCR ) , persist least 3 month , patient chronic phase chronic myelogenous leukemia . - Determine percentage patient treat vaccine become RT-PCR-negative BCR-ABL transcript . - Compare response patient B3A2 junction vs B2A2 junction treat vaccine . - Determine immunologic response 1 year patient treat vaccine . - Correlate response specific HLA type patient . - Determine safety vaccine patient . OUTLINE : This pilot , multicenter study . Patients receive BCR-ABL junction-specific peptide vaccine subcutaneously week 2 , 4 , 6 , 8 , 11 monthly 10 month . BCR-ABL transcript level assess quantitative reverse-transcriptase polymerase chain reaction baseline , week 2 , 4 , 6 , every 3 month treatment , 2 week completion study treatment . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Philadelphia chromosomepositive BCRABLpositive chronic phase chronic myelogenous leukemia ( CML ) In complete cytogenetic remission confirm 2 bone marrow ≥ 1 month apart Minimal residual disease Detectable BCRABL transcript level obtain &lt; 6 month apart AND ≤ 0.5log low low value obtain within past 6 month PATIENT CHARACTERISTICS : Karnofsky performance status 80100 % Bilirubin &lt; 2 time upper limit normal ( ULN ) Creatinine &lt; 1.5 time ULN ALT AST &lt; 2.5 time ULN PRIOR CONCURRENT THERAPY : Recovered prior therapy No major surgery within past 4 week No prior chemotherapy No prior immunosuppressive therapy No prior corticosteroids No prior stem cell transplantation No radiotherapy within past 4 week No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Philadelphia chromosome positive ( Ph+ ) chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
</DOC>